Aprogen, Inc Logo

Aprogen, Inc

Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.

007460 | KO

Overview

Corporate Details

ISIN(s):
KR7007460009
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로 545 경기도 성남시 중원구 둔촌대로545, 비1층 (상대원동, 한라시그마밸리), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprogen, Inc. is a biopharmaceutical company specializing in the development and manufacturing of biologics. Leveraging proprietary technologies in antibody and recombinant protein engineering, the company creates both novel drugs and biosimilars. Its product pipeline focuses on addressing various medical needs, including treatments for degenerative arthritis and triple-negative breast cancer. Aprogen develops its own portfolio of biologics alongside biosimilar products, aiming to make advanced medicines more accessible in the global pharmaceutical market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 151.1 KB
2025-09-17 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 15.5 KB
2025-09-03 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)(자회사의 주요경영사항) (제3자배정)
Korean 31.1 KB
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 157.0 KB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 149.8 KB
2025-08-19 00:00
Regulatory News Service
투자판단관련주요경영사항 (독점실시권 라이선스 계약(면역항암제 기술도입 계약))
Korean 10.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 7.7 MB
2025-07-31 00:00
Regulatory News Service
단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Korean 10.4 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 155.6 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 148.5 KB
2025-06-27 00:00
Capital/Financing Update
[기재정정]주권관련사채권의처분결정(종속회사의주요경영사항)
Korean 23.5 KB
2025-06-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.3 KB
2025-06-09 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-06-02 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-05-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.4 KB

Automate Your Workflow. Get a real-time feed of all Aprogen, Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprogen, Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprogen, Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.